Trovafloxacin

Edina Avdic, Pharm.D., Paul A. Pham, Pharm.D.
Trovafloxacin is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Before pulled from the U.S. market for hepatotoxicity reasons, the use of trovafloxacin was reserved for use only if the patient meets all of the following criteria:
    • Has at least one of the following infections that is judged by the treating physician to be serious and life- or limb-threatening:
    • Receives initial therapy in an in-patient heath care facility (i.e., hospital or long-term nursing care facility).
    • The treating physician believes that, even given the new safety information, the benefit of the product for the patient outweighs the potential risk.
    • Use of trovafloxacin was limited to 14 days or less.

NON-FDA APPROVED USES

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • Before pulled from the U.S. market for hepatotoxicity reasons, the use of trovafloxacin was reserved for use only if the patient meets all of the following criteria:
    • Has at least one of the following infections that is judged by the treating physician to be serious and life- or limb-threatening:
    • Receives initial therapy in an in-patient heath care facility (i.e., hospital or long-term nursing care facility).
    • The treating physician believes that, even given the new safety information, the benefit of the product for the patient outweighs the potential risk.
    • Use of trovafloxacin was limited to 14 days or less.

NON-FDA APPROVED USES

There's more to see -- the rest of this topic is available only to subscribers.

© 2000–2022 Unbound Medicine, Inc. All rights reserved